The global Poliovirus Vaccine market size will be USD 821.2 million in 2024.

Name: Global Poliovirus Vaccine Market Analysis 2026
Brand: Cognitive Market Research
SKU: CMR402490
Rating: 4.8 (19 reviews)
Author: Supriya Yadav

Data Timeline	Historical Data: 2022–2025 \| Base Year: 2025 \| Forecast Period: 2026–2034
Type Segment	Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV))
End Users Segment	Hospitals, Homecare, Specialty Clinics, Others

Application Segment	Public, Private
Regions & Countries	North America (United States, Canada, Mexico) Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe) Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC) South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America) Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East) Africa (East Africa, West Africa, North Africa, South Africa)

Contents

Global Poliovirus Vaccine Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Loading…

Share Distribution

Loading…

Market Dynamics of Global Poliovirus Vaccine Market Analysis

↑ Growth Drivers

Rising polio eradication programs globally Innovations in vaccine technologies Rising immunization programs

↓ Restraints

The public's distrust is a result of vaccine-derived poliovirus (VDPV) outbreaks Logistical difficulties in getting vaccines to remote areas to hinder market growth

~ Trends

Growing preference for inactivated poliovirus vaccine (IPV) Increasing funding for vaccine development and research to produce better formulations

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Global Poliovirus Vaccine Market Analysis — Presence

Interactive World Map

Click countries to explore

Loading map…

Regional and Country Analysis

North America — United States, Canada, Mexico
Europe — United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe
Asia Pacific — China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC
South America — Brazil, Argentina, Colombia, Peru, Chile, Rest of South America
Middle East — Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East
Africa — East Africa, West Africa, North Africa, South Africa

Region / Country	2021 (A)	2025 (A)	2033 (P)	CAGR

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Market size by (Illustrative, 2025)

Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitive Landscape of the Poliovirus Vaccine Market

A competitive landscape with major competitors, including Sanofi Pasteur, GSK, Serum Institute of India, and Bharat Biotech, characterizes the poliovirus vaccine market. These businesses concentrate on developing new products, refining vaccine formulas, and increasing production capacities. Governments and international health organizations work together to improve accessibility and distribution. Businesses are investing in cutting-edge production processes and research in order to stay relevant in the market as the move toward inactivated poliovirus vaccines, or IPVs gathers steam.

In January 2024, the United Nations Children's Fund (UNICEF) donated 340,000 oral polio vaccine (OPV) pills to Ukraine in support of the country's National Immunization Program, protecting children against a potentially fatal virus. The US Agency for International Development (USAID) provided assistance for this effort. (Source: https://www.unicef.org/ukraine/en/press-releases/unicef-delivers-oral-polio-vaccine) In March 2021 and September 2020, Sanofi S.A.'s Canadian manufacturing facility announced that it would invest over 600 million euros in the development of new vaccines. This will benefit the company's product range and portfolio. (Source:https://www.sanofi.com/en/media-room/press-releases/2021/2021-03-31-14-05-00-2202566) In September 2020, Sanofi Pasteur India announced the launch of Tetraxim (DTaP-IPV), a booster vaccine that protects against tetanus, pertussis, diphtheria, and polio and is advised for preschool-aged children. (Source:https://www.sanofi.in/dam/jcr:c7dd91d8-d5ad-4e6e-9e71-6b7c6661ae37/sanofi_pasteur_launches_tetraxim.pdf)

Click any bar or cell to request the full company profile

Company	2022 (A)	2023 (A)	2024 (A)	2025 (A)
Pfizer Inc. (U.S.)	•••	•••	•••	•••
Mylan N.V. (U.S.)	•••	•••	•••	•••
Sanofi (France)	•••	•••	•••	•••
GSK plc (U.K.)	•••	•••	•••	•••
Novartis AG (Switzerland)	•••	•••	•••	•••
F. Hoffmann-La Roche Ltd. (Switzerland)	•••	•••	•••	•••
Bristol-Myers Squibb Company (U.S.)	•••	•••	•••	•••
Boehringer Ingelheim International GmbH. (Germany)	•••	•••	•••	•••
Merck & Co.	•••	•••	•••	•••
Inc. (U.S.)	•••	•••	•••	•••
Serum Institute of India Pvt. Ltd (India)	•••	•••	•••	•••
BIO-MED (India)	•••	•••	•••	•••
Astellas Pharma Inc. (Japan)	•••	•••	•••	•••
HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India)	•••	•••	•••	•••

Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Poliovirus Vaccine market size was USD 821.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.20% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 328.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 246.36 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 188.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 41.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 16.42 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
The supplements are the fastest growing segment of the Poliovirus Vaccine industry

Introduction of the Poliovirus Vaccine Market

The goal of the poliovirus vaccine market is to prevent polio, a viral disease that can spread quickly and result in paralysis or even death. Oral polio vaccine (OPV), which is simple to give but contains a risk of vaccine-derived poliovirus, and inactivated polio vaccine (IPV), which is safer but more costly and needs to be injected by qualified staff, are the two main forms of immunizations. Government immunization programs, growing public health awareness, and worldwide eradication initiatives are driving forces behind the industry. But there are obstacles like exorbitant prices, logistical problems getting immunizations to far-flung places, and the shift from OPV to IPV that make things complicated. Market dynamics are still being shaped by ongoing technological developments in vaccines and expanding global alliances.

In June 2024, Sanofi and Biovac, a biopharmaceutical firm, announced that they would be collaborating on local manufacturing to make inactivated polio vaccines (IPV) in Africa. (Source: https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-20-12-00-00-2901636)

Global Poliovirus Vaccine Market Analysis Insights Video

Analyst Conclusion

Conclusion

The global Poliovirus Vaccine market will expand significantly by 5.20% CAGR between 2024 and 2031.
The oral polio vaccine (OPV) is much sought after since it is inexpensive, easy to administer, and can create herd immunity during vaccination campaigns. This is especially true in underdeveloped countries.
The administration of vaccines, especially the inactivated polio vaccine (IPV), is made easier by hospitals, which also guarantee effective immunization thanks to their well-established healthcare infrastructure and highly skilled staff. Hospitals are crucial end-users in the poliovirus vaccine market.

Supriya Yadav

Research Analyst · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence. Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics. In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments. Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

LinkedIn Profile Book Appointment

Frequently Asked Questions

What is the market size for the Poliovirus Vaccine market in 2024?

The global market size for Poliovirus Vaccine in 2024 is USD 821.2 million.

What is the growth rate for the Poliovirus Vaccine market over the forecast period?

The global Poliovirus Vaccine market is expected to grow with a CAGR of 5.20% over the projected period.

Which is the leading region of the market for Poliovirus vaccines?

North America held a significant global Poliovirus Vaccine market revenue share in 2024.

Which region is projected to detect the fastest growth in the Poliovirus Vaccine market over the forecast period?

Asia-Pacific will witness the fastest growth of the global Poliovirus Vaccine market over the coming years.

Which country will be leading in the Poliovirus Vaccine market in 2024?

The US had the most significant global Poliovirus Vaccine market revenue share in 2024.

What are the key drivers for the growth of the Poliovirus Vaccine market?

The main driver of the growth of the Poliovirus Vaccine market is the increase in routine immunization coverage and expanded cold chain infrastructure.

Which is the significant Poliovirus Vaccine market segment by type?

The oral polio vaccine (OPV)) category dominates the market.

★ Reviews

Rate this report

Global Poliovirus Vaccine Market Analysis — Table of Contents

Disclaimer: Redacted sample for representative purposes. Charts and data do not depict actual statistics. TOC varies by license selection.

Type	Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV))
End Users	Hospitals, Homecare, Specialty Clinics, Others
Application	Public, Private
List of Competitors	Pfizer Inc. (U.S.), Mylan N.V. (U.S.), Sanofi (France), GSK plc (U.K.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co., Inc. (U.S.), Serum Institute of India Pvt. Ltd (India), BIO-MED (India), Astellas Pharma Inc. (Japan), HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India)

1.1 Global Power Realignment & Strategic Alliances
1.2 Geopolitical Risk Landscape & Conflict Hotspots
1.3 International Trade Relations & Market Access Environment
1.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
1.5 Supply Chain Resilience, Localization & Resource Nationalism
1.6 Technology Sovereignty & Digital Geopolitics
1.7 Strategic Implications for Investment, Growth & Market Entry

2.1 Competitive Landscape Disruption & Strategic Shifts
2.2 AI-Driven Transformation of Industry Value Chain
2.3 Evolution of Business Models & Revenue Streams
2.4 Operational Efficiency & Cost Structure Transformation
2.5 Product, Service & Innovation Acceleration
2.6 Customer Behavior & Demand Evolution
2.7 Future Outlook: AI-Led Market Evolution & Strategic Implications

3.1 Global Poliovirus Vaccine Revenue Market Size, Trend Analysis 2022 - 2034
3.2 Global Poliovirus Vaccine Volume Market Sales, Trend Analysis 2022 - 2034
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

3.3 Global Poliovirus Vaccine Market Size By Regions 2022 - 2034
- 3.3.1 Global Poliovirus Vaccine Revenue Market Size By Region
- 3.3.2 Global Poliovirus Vaccine Volume Market Sales By Region
3.4 Global Poliovirus Vaccine Market Size By Type 2022 - 2034
- 3.4.1 Inactivated Polio Vaccine (IPV) Market Size
- 3.4.2 Oral Polio Vaccine (OPV)) Market Size
3.5 Global Poliovirus Vaccine Volume Market Sales By Type 2022 - 2034
- 3.5.1 Inactivated Polio Vaccine (IPV) Sales Volume
- 3.5.2 Oral Polio Vaccine (OPV)) Sales Volume
3.6 Global Poliovirus Vaccine Market Size By End Users 2022 - 2034
- 3.6.1 Hospitals Market Size
- 3.6.2 Homecare Market Size
- 3.6.3 Specialty Clinics Market Size
- 3.6.4 Others Market Size
3.7 Global Poliovirus Vaccine Volume Market Sales By End Users 2022 - 2034
- 3.7.1 Hospitals Sales Volume
- 3.7.2 Homecare Sales Volume
- 3.7.3 Specialty Clinics Sales Volume
- 3.7.4 Others Sales Volume
3.8 Global Poliovirus Vaccine Market Size By Application 2022 - 2034
- 3.8.1 Public Market Size
- 3.8.2 Private Market Size
3.9 Global Poliovirus Vaccine Volume Market Sales By Application 2022 - 2034
- 3.9.1 Public Sales Volume
- 3.9.2 Private Sales Volume
3.10 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

3.11 Executive Summary Global Market (2021 vs 2025 vs 2033)
- 3.11.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
- 3.11.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
- 3.11.3 Global Market Revenue Split By Type
- 3.11.4 Global Volume Market Split By Type
- 3.11.5 Global Market Revenue Split By End Users
- 3.11.6 Global Volume Market Split By End Users
- 3.11.7 Global Market Revenue Split By Application
- 3.11.8 Global Volume Market Split By Application
- Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
  
  3.11.9 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

4.1 North America Poliovirus Vaccine Market Outlook
- 4.1.1 North America Poliovirus Vaccine Market Size 2022 - 2034
- 4.1.2 North America Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 4.1.3 North America Poliovirus Vaccine Market Size By Country 2022 - 2034
- 4.1.4 North America Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 4.1.5 North America Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 4.1.5.1 North America Inactivated Polio Vaccine (IPV) Market Size
  - 4.1.5.2 North America Oral Polio Vaccine (OPV)) Market Size
- 4.1.6 North America Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 4.1.6.1 North America Inactivated Polio Vaccine (IPV) Sales Volume
  - 4.1.6.2 North America Oral Polio Vaccine (OPV)) Sales Volume
- 4.1.7 North America Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 4.1.7.1 North America Hospitals Market Size
  - 4.1.7.2 North America Homecare Market Size
  - 4.1.7.3 North America Specialty Clinics Market Size
  - 4.1.7.4 North America Others Market Size
- 4.1.8 North America Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 4.1.8.1 North America Hospitals Sales Volume
  - 4.1.8.2 North America Homecare Sales Volume
  - 4.1.8.3 North America Specialty Clinics Sales Volume
  - 4.1.8.4 North America Others Sales Volume
- 4.1.9 North America Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 4.1.9.1 North America Public Market Size
  - 4.1.9.2 North America Private Market Size
- 4.1.10 North America Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 4.1.10.1 North America Public Sales Volume
  - 4.1.10.2 North America Private Sales Volume

5.1 Europe Poliovirus Vaccine Market Outlook
- 5.1.1 Europe Poliovirus Vaccine Market Size 2022 - 2034
- 5.1.2 Europe Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 5.1.3 Europe Poliovirus Vaccine Market Size By Country 2022 - 2034
- 5.1.4 Europe Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 5.1.5 Europe Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 5.1.5.1 Europe Inactivated Polio Vaccine (IPV) Market Size
  - 5.1.5.2 Europe Oral Polio Vaccine (OPV)) Market Size
- 5.1.6 Europe Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 5.1.6.1 Europe Inactivated Polio Vaccine (IPV) Sales Volume
  - 5.1.6.2 Europe Oral Polio Vaccine (OPV)) Sales Volume
- 5.1.7 Europe Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 5.1.7.1 Europe Hospitals Market Size
  - 5.1.7.2 Europe Homecare Market Size
  - 5.1.7.3 Europe Specialty Clinics Market Size
  - 5.1.7.4 Europe Others Market Size
- 5.1.8 Europe Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 5.1.8.1 Europe Hospitals Sales Volume
  - 5.1.8.2 Europe Homecare Sales Volume
  - 5.1.8.3 Europe Specialty Clinics Sales Volume
  - 5.1.8.4 Europe Others Sales Volume
- 5.1.9 Europe Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 5.1.9.1 Europe Public Market Size
  - 5.1.9.2 Europe Private Market Size
- 5.1.10 Europe Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 5.1.10.1 Europe Public Sales Volume
  - 5.1.10.2 Europe Private Sales Volume

6.1 Asia Pacific Poliovirus Vaccine Market Outlook
- 6.1.1 Asia Pacific Poliovirus Vaccine Market Size 2022 - 2034
- 6.1.2 Asia Pacific Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 6.1.3 Asia Pacific Poliovirus Vaccine Market Size By Country 2022 - 2034
- 6.1.4 Asia Pacific Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 6.1.5 Asia Pacific Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 6.1.5.1 Asia Pacific Inactivated Polio Vaccine (IPV) Market Size
  - 6.1.5.2 Asia Pacific Oral Polio Vaccine (OPV)) Market Size
- 6.1.6 Asia Pacific Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 6.1.6.1 Asia Pacific Inactivated Polio Vaccine (IPV) Sales Volume
  - 6.1.6.2 Asia Pacific Oral Polio Vaccine (OPV)) Sales Volume
- 6.1.7 Asia Pacific Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 6.1.7.1 Asia Pacific Hospitals Market Size
  - 6.1.7.2 Asia Pacific Homecare Market Size
  - 6.1.7.3 Asia Pacific Specialty Clinics Market Size
  - 6.1.7.4 Asia Pacific Others Market Size
- 6.1.8 Asia Pacific Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 6.1.8.1 Asia Pacific Hospitals Sales Volume
  - 6.1.8.2 Asia Pacific Homecare Sales Volume
  - 6.1.8.3 Asia Pacific Specialty Clinics Sales Volume
  - 6.1.8.4 Asia Pacific Others Sales Volume
- 6.1.9 Asia Pacific Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 6.1.9.1 Asia Pacific Public Market Size
  - 6.1.9.2 Asia Pacific Private Market Size
- 6.1.10 Asia Pacific Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 6.1.10.1 Asia Pacific Public Sales Volume
  - 6.1.10.2 Asia Pacific Private Sales Volume

7.1 South America Poliovirus Vaccine Market Outlook
- 7.1.1 South America Poliovirus Vaccine Market Size 2022 - 2034
- 7.1.2 South America Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 7.1.3 South America Poliovirus Vaccine Market Size By Country 2022 - 2034
- 7.1.4 South America Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 7.1.5 South America Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 7.1.5.1 South America Inactivated Polio Vaccine (IPV) Market Size
  - 7.1.5.2 South America Oral Polio Vaccine (OPV)) Market Size
- 7.1.6 South America Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 7.1.6.1 South America Inactivated Polio Vaccine (IPV) Sales Volume
  - 7.1.6.2 South America Oral Polio Vaccine (OPV)) Sales Volume
- 7.1.7 South America Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 7.1.7.1 South America Hospitals Market Size
  - 7.1.7.2 South America Homecare Market Size
  - 7.1.7.3 South America Specialty Clinics Market Size
  - 7.1.7.4 South America Others Market Size
- 7.1.8 South America Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 7.1.8.1 South America Hospitals Sales Volume
  - 7.1.8.2 South America Homecare Sales Volume
  - 7.1.8.3 South America Specialty Clinics Sales Volume
  - 7.1.8.4 South America Others Sales Volume
- 7.1.9 South America Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 7.1.9.1 South America Public Market Size
  - 7.1.9.2 South America Private Market Size
- 7.1.10 South America Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 7.1.10.1 South America Public Sales Volume
  - 7.1.10.2 South America Private Sales Volume

8.1 Middle East Poliovirus Vaccine Market Outlook
- 8.1.1 Middle East Poliovirus Vaccine Market Size 2022 - 2034
- 8.1.2 Middle East Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 8.1.3 Middle East Poliovirus Vaccine Market Size By Country 2022 - 2034
- 8.1.4 Middle East Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 8.1.5 Middle East Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 8.1.5.1 Middle East Inactivated Polio Vaccine (IPV) Market Size
  - 8.1.5.2 Middle East Oral Polio Vaccine (OPV)) Market Size
- 8.1.6 Middle East Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 8.1.6.1 Middle East Inactivated Polio Vaccine (IPV) Sales Volume
  - 8.1.6.2 Middle East Oral Polio Vaccine (OPV)) Sales Volume
- 8.1.7 Middle East Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 8.1.7.1 Middle East Hospitals Market Size
  - 8.1.7.2 Middle East Homecare Market Size
  - 8.1.7.3 Middle East Specialty Clinics Market Size
  - 8.1.7.4 Middle East Others Market Size
- 8.1.8 Middle East Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 8.1.8.1 Middle East Hospitals Sales Volume
  - 8.1.8.2 Middle East Homecare Sales Volume
  - 8.1.8.3 Middle East Specialty Clinics Sales Volume
  - 8.1.8.4 Middle East Others Sales Volume
- 8.1.9 Middle East Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 8.1.9.1 Middle East Public Market Size
  - 8.1.9.2 Middle East Private Market Size
- 8.1.10 Middle East Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 8.1.10.1 Middle East Public Sales Volume
  - 8.1.10.2 Middle East Private Sales Volume

9.1 Africa Poliovirus Vaccine Market Outlook
- 9.1.1 Africa Poliovirus Vaccine Market Size 2022 - 2034
- 9.1.2 Africa Poliovirus Vaccine Volume Market Sales 2022 - 2034
- 9.1.3 Africa Poliovirus Vaccine Market Size By Country 2022 - 2034
- 9.1.4 Africa Poliovirus Vaccine Volume Market Sales By Country 2022 - 2034
- 9.1.5 Africa Poliovirus Vaccine Market Size by Type 2022 - 2034
  - 9.1.5.1 Africa Inactivated Polio Vaccine (IPV) Market Size
  - 9.1.5.2 Africa Oral Polio Vaccine (OPV)) Market Size
- 9.1.6 Africa Poliovirus Vaccine Volume Market Sales by Type 2022 - 2034
  - 9.1.6.1 Africa Inactivated Polio Vaccine (IPV) Sales Volume
  - 9.1.6.2 Africa Oral Polio Vaccine (OPV)) Sales Volume
- 9.1.7 Africa Poliovirus Vaccine Market Size by End Users 2022 - 2034
  - 9.1.7.1 Africa Hospitals Market Size
  - 9.1.7.2 Africa Homecare Market Size
  - 9.1.7.3 Africa Specialty Clinics Market Size
  - 9.1.7.4 Africa Others Market Size
- 9.1.8 Africa Poliovirus Vaccine Volume Market Sales by End Users 2022 - 2034
  - 9.1.8.1 Africa Hospitals Sales Volume
  - 9.1.8.2 Africa Homecare Sales Volume
  - 9.1.8.3 Africa Specialty Clinics Sales Volume
  - 9.1.8.4 Africa Others Sales Volume
- 9.1.9 Africa Poliovirus Vaccine Market Size by Application 2022 - 2034
  - 9.1.9.1 Africa Public Market Size
  - 9.1.9.2 Africa Private Market Size
- 9.1.10 Africa Poliovirus Vaccine Volume Market Sales by Application 2022 - 2034
  - 9.1.10.1 Africa Public Sales Volume
  - 9.1.10.2 Africa Private Sales Volume

10.1 Top Competitors Analysis
- (Subject to Data Availability (Private Players))
  
  10.1.1 Global Poliovirus Vaccine Market Revenue and Share by Key Players
- 10.1.2 Global Poliovirus Vaccine Market Volume and Share by Key Players
- 10.1.3 Top Players Ranking 2024
- 10.1.4 New Product Launch Analysis
- 10.1.5 Industry Mergers and Acquisition Analysis
10.2 Company Profile (Data Subject to Availability) Sample Format
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.1 Pfizer Inc. (U.S.)
  - 10.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.1.2 Business Overview
  - 10.2.1.3 Financials (Subject to data availability)
  - 10.2.1.4 R&D Investment (Subject to data availability)
  - 10.2.1.5 Product Types Specification
  - 10.2.1.6 Business Strategy
  - 10.2.1.7 Recent Developments
  - 10.2.1.8 Management Change
  - 10.2.1.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.2 Mylan N.V. (U.S.)
  - 10.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.2.2 Business Overview
  - 10.2.2.3 Financials (Subject to data availability)
  - 10.2.2.4 R&D Investment (Subject to data availability)
  - 10.2.2.5 Product Types Specification
  - 10.2.2.6 Business Strategy
  - 10.2.2.7 Recent Developments
  - 10.2.2.8 Management Change
  - 10.2.2.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.3 Sanofi (France)
  - 10.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.3.2 Business Overview
  - 10.2.3.3 Financials (Subject to data availability)
  - 10.2.3.4 R&D Investment (Subject to data availability)
  - 10.2.3.5 Product Types Specification
  - 10.2.3.6 Business Strategy
  - 10.2.3.7 Recent Developments
  - 10.2.3.8 Management Change
  - 10.2.3.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.4 GSK plc (U.K.)
  - 10.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.4.2 Business Overview
  - 10.2.4.3 Financials (Subject to data availability)
  - 10.2.4.4 R&D Investment (Subject to data availability)
  - 10.2.4.5 Product Types Specification
  - 10.2.4.6 Business Strategy
  - 10.2.4.7 Recent Developments
  - 10.2.4.8 Management Change
  - 10.2.4.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.5 Novartis AG (Switzerland)
  - 10.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.5.2 Business Overview
  - 10.2.5.3 Financials (Subject to data availability)
  - 10.2.5.4 R&D Investment (Subject to data availability)
  - 10.2.5.5 Product Types Specification
  - 10.2.5.6 Business Strategy
  - 10.2.5.7 Recent Developments
  - 10.2.5.8 Management Change
  - 10.2.5.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.6 F. Hoffmann-La Roche Ltd. (Switzerland)
  - 10.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.6.2 Business Overview
  - 10.2.6.3 Financials (Subject to data availability)
  - 10.2.6.4 R&D Investment (Subject to data availability)
  - 10.2.6.5 Product Types Specification
  - 10.2.6.6 Business Strategy
  - 10.2.6.7 Recent Developments
  - 10.2.6.8 Management Change
  - 10.2.6.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.7 Bristol-Myers Squibb Company (U.S.)
  - 10.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.7.2 Business Overview
  - 10.2.7.3 Financials (Subject to data availability)
  - 10.2.7.4 R&D Investment (Subject to data availability)
  - 10.2.7.5 Product Types Specification
  - 10.2.7.6 Business Strategy
  - 10.2.7.7 Recent Developments
  - 10.2.7.8 Management Change
  - 10.2.7.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.8 Boehringer Ingelheim International GmbH. (Germany)
  - 10.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.8.2 Business Overview
  - 10.2.8.3 Financials (Subject to data availability)
  - 10.2.8.4 R&D Investment (Subject to data availability)
  - 10.2.8.5 Product Types Specification
  - 10.2.8.6 Business Strategy
  - 10.2.8.7 Recent Developments
  - 10.2.8.8 Management Change
  - 10.2.8.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.9 Merck & Co.
  - 10.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.9.2 Business Overview
  - 10.2.9.3 Financials (Subject to data availability)
  - 10.2.9.4 R&D Investment (Subject to data availability)
  - 10.2.9.5 Product Types Specification
  - 10.2.9.6 Business Strategy
  - 10.2.9.7 Recent Developments
  - 10.2.9.8 Management Change
  - 10.2.9.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.10 Inc. (U.S.)
  - 10.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.10.2 Business Overview
  - 10.2.10.3 Financials (Subject to data availability)
  - 10.2.10.4 R&D Investment (Subject to data availability)
  - 10.2.10.5 Product Types Specification
  - 10.2.10.6 Business Strategy
  - 10.2.10.7 Recent Developments
  - 10.2.10.8 Management Change
  - 10.2.10.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.11 Serum Institute of India Pvt. Ltd (India)
  - 10.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.11.2 Business Overview
  - 10.2.11.3 Financials (Subject to data availability)
  - 10.2.11.4 R&D Investment (Subject to data availability)
  - 10.2.11.5 Product Types Specification
  - 10.2.11.6 Business Strategy
  - 10.2.11.7 Recent Developments
  - 10.2.11.8 Management Change
  - 10.2.11.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.12 BIO-MED (India)
  - 10.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.12.2 Business Overview
  - 10.2.12.3 Financials (Subject to data availability)
  - 10.2.12.4 R&D Investment (Subject to data availability)
  - 10.2.12.5 Product Types Specification
  - 10.2.12.6 Business Strategy
  - 10.2.12.7 Recent Developments
  - 10.2.12.8 Management Change
  - 10.2.12.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.13 Astellas Pharma Inc. (Japan)
  - 10.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.13.2 Business Overview
  - 10.2.13.3 Financials (Subject to data availability)
  - 10.2.13.4 R&D Investment (Subject to data availability)
  - 10.2.13.5 Product Types Specification
  - 10.2.13.6 Business Strategy
  - 10.2.13.7 Recent Developments
  - 10.2.13.8 Management Change
  - 10.2.13.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.14 HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India)
  - 10.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.14.2 Business Overview
  - 10.2.14.3 Financials (Subject to data availability)
  - 10.2.14.4 R&D Investment (Subject to data availability)
  - 10.2.14.5 Product Types Specification
  - 10.2.14.6 Business Strategy
  - 10.2.14.7 Recent Developments
  - 10.2.14.8 Management Change
  - 10.2.14.9 S.W.O.T Analysis

11.1 Market Drivers
11.2 Market Restraints
11.3 Market Trends
11.4 Market Opportunity
11.5 Technological Road Map (Subject to Data Availability)
11.6 Product Life Cycle (Subject to Data Availability)
11.7 Customer and Buyer Behavior Analysis
- 11.7.1 Consumer Demographics and Target Audience Assessment
- 11.7.2 Consumer Purchase Behavior and Demand Assessment
- 11.7.3 Consumer Pricing Dynamics and Affordability Assessment
- 11.7.4 Digital Consumer Engagement and Online Adoption Analysis
- 11.7.5 Future Consumption Trends and Demand Evolution Analysis
- 11.7.6 Enterprise Procurement & Purchasing Behavior Analysis
- 11.7.7 Buyer Decision-Making & Purchase Influence Assessment
- 11.7.8 Customer Expectations & Service Experience Evaluation
- 11.7.9 Vendor Selection & Supplier Preference Analysis
- 11.7.10 Customer Retention & Loyalty Strategy Assessment
- 11.7.11 Pricing Sensitivity & Value Perception Analysis
- 11.7.12 Customer Segmentation & Demand Pattern Analysis
- 11.7.13 Relationship Management & Strategic Partnership Trends
11.8 Market Attractiveness Analysis
11.9 PESTEL Analysis
- 11.9.1 Political Factors
- 11.9.2 Economic Factors
- 11.9.3 Social Factors
- 11.9.4 Technological Factors
- 11.9.5 Legal Factors
- 11.9.6 Environmental Factors
11.10 Industrial Chain Analysis (Subject to Data Availability)
- 11.10.1 Industry Chain Analysis
- 11.10.2 Manufacturing Cost Analysis
- 11.10.3 Supply Side Analysis
  - 11.10.3.1 Raw Material Analysis
  - 11.10.3.2 Raw Material Procurement Analysis
  - 11.10.3.3 Raw Material Price Trend Analysis
11.11 Porter’s Five Forces Analysis
- 11.11.1 Bargaining Power of Suppliers
- 11.11.2 Bargaining Power of Buyers
- 11.11.3 Threat of New Entrants
- 11.11.4 Threat of Substitutes
- 11.11.5 Degree of Competition
11.12 Patent Analysis (Subject to Data Availability)
11.13 ESG Analysis

12.1 Inactivated Polio Vaccine (IPV)
- 12.1.1 Global Poliovirus Vaccine Revenue Market Size and Share by Inactivated Polio Vaccine (IPV) 2022 - 2034
- 12.1.2 Global Poliovirus Vaccine Volume Market Sales by Inactivated Polio Vaccine (IPV) 2022 - 2034
12.2 Oral Polio Vaccine (OPV))
- 12.2.1 Global Poliovirus Vaccine Revenue Market Size and Share by Oral Polio Vaccine (OPV)) 2022 - 2034
- 12.2.2 Global Poliovirus Vaccine Volume Market Sales by Oral Polio Vaccine (OPV)) 2022 - 2034

13.1 Hospitals
- 13.1.1 Global Poliovirus Vaccine Revenue Market Size and Share by Hospitals 2022 - 2034
- 13.1.2 Global Poliovirus Vaccine Volume Market Sales by Hospitals 2022 - 2034
13.2 Homecare
- 13.2.1 Global Poliovirus Vaccine Revenue Market Size and Share by Homecare 2022 - 2034
- 13.2.2 Global Poliovirus Vaccine Volume Market Sales by Homecare 2022 - 2034
13.3 Specialty Clinics
- 13.3.1 Global Poliovirus Vaccine Revenue Market Size and Share by Specialty Clinics 2022 - 2034
- 13.3.2 Global Poliovirus Vaccine Volume Market Sales by Specialty Clinics 2022 - 2034
13.4 Others
- 13.4.1 Global Poliovirus Vaccine Revenue Market Size and Share by Others 2022 - 2034
- 13.4.2 Global Poliovirus Vaccine Volume Market Sales by Others 2022 - 2034

14.1 Public
- 14.1.1 Global Poliovirus Vaccine Revenue Market Size and Share by Public 2022 - 2034
- 14.1.2 Global Poliovirus Vaccine Volume Market Sales by Public 2022 - 2034
14.2 Private
- 14.2.1 Global Poliovirus Vaccine Revenue Market Size and Share by Private 2022 - 2034
- 14.2.2 Global Poliovirus Vaccine Volume Market Sales by Private 2022 - 2034

15.1 Company Gap Assessment Analysis
15.2 Product & Service Portfolio Gap Analysis
15.3 Demand-Supply Imbalance Analysis
15.4 Market Opportunity & Unmet Needs Analysis
15.5 Technology Adoption & Digital Transformation Gap Analysis
15.6 Operational Efficiency & Process Gap Analysis
15.7 Infrastructure & Capacity Gap Analysis
15.8 Geographic Coverage & Distribution Gap Analysis
15.9 Investment Opportunity & Funding Gap Analysis
15.10 Pricing Structure & Margin Gap Analysis
15.11 Innovation & R&D Capability Gap Analysis
15.12 Policy, Compliance & Regulatory Gap Analysis
15.13 Customer Experience & Expectation Gap Analysis
15.14 Future Growth Opportunity Gap Analysis
15.15 Market Accessibility & Penetration Gap Analysis

16.1 Strategic Commercialization & Pricing Assessment

17.1 Gross Margin Overview and Industry Profitability Trends
17.2 Regional Gross Margin Performance Analysis
17.3 Supply Chain and Distribution Impact on Gross Margins
17.4 Pricing Strategy and Value-Added Margin Assessment
17.5 Key Factors Influencing Gross Margin Variability
17.6 Future Gross Margin Outlook and Profitability Trends

18.1 Key Takeaways
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

18.2 Analyst Point of View
18.3 Assumptions and Acronyms

19.1 Primary Data Collection
- 19.1.1 Steps for Primary Data Collection
  - 19.1.1.1 Identification of KOL
- 19.1.2 Backward Integration
- 19.1.3 Forward Integration
- 19.1.4 How Primary Research Help Us
- 19.1.5 Modes of Primary Research
19.2 Secondary Research
- 19.2.1 How Secondary Research Help Us
- 19.2.2 Sources of Secondary Research
19.3 Data Validation
- 19.3.1 Data Triangulation
- 19.3.2 Top Down & Bottom Up Approach
- 19.3.3 Cross check KOL Responses with Secondary Data
19.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Global Poliovirus Vaccine Market Analysis Market analysis.

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics

Data Points Validated 10,400+

Expert Interviews 54

Countries Covered 39+

Company Profiles 14+

Forecast Accuracy (Historical) 94.2%

Report Pages 250+

Analytical Coverage

Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Poliovirus Vaccine Market

Sources from Pharma & Healthcare Industry

How We Serve You

Three Pillars of Market Intelligence

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Global Poliovirus Vaccine Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the global poliovirus vaccine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included

Buyer intent & sentiment analysis
Purchase cycle mapping
Price sensitivity research
Channel preference profiling
Competitive perception study

Most Requested

Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included

Ready syndicate report (250+ pages)
Custom data scope & segmentation
Excel quantitative models
Board-ready PPT with key findings
Secure cloud portal access

Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included